17 abril 2014

CIRCULATION. Valvular Heart Disease. Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation

Anthony W. Castleberry, MD, MMCi; Judson B. Williams, MD, MHS; Mani A. Daneshmand, MD; Emily Honeycutt, MBI; Linda K. Shaw, MS; Zainab Samad, MD, MHS; Renato D. Lopes, MD, PhD; John H. Alexander, MD, MHS; Joseph P. Mathew, MD, MHSc; Eric J. Velazquez, MD; Carmelo A. Milano, MD; Peter K. Smith, MD

Background: The optimal treatment for ischemic mitral regurgitation remains actively debated. Our objective was to evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival.

03 abril 2014

CIRCULATION. Interventional Cardiology. Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial

Marie-Claude Morice, MD; Patrick W. Serruys, MD, PhD; A. Pieter Kappetein, MD, PhD; Ted E. Feldman, MD; Elisabeth Ståhle, MD; Antonio Colombo, MD; Michael J. Mack, MD; David R. Holmes, MD; James W. Choi, MD; Witold Ruzyllo, MD; Grzegorz Religa, MD; Jian Huang, MD, MS; Kristine Roy, PhD; Keith D. Dawkins, MD; Friedrich Mohr, MD, PhD

Background: Current guidelines recommend coronary artery bypass graft surgery (CABG) when treating significant de novo left main coronary artery (LM) stenosis; however, percutaneous coronary intervention (PCI) has a class IIa indication for unprotected LM disease in selected patients. This analysis compares 5-year clinical outcomes in PCI- and CABG-treated LM patients in the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial, the largest trial in this group to date.

25 marzo 2014

CIRCULATION. Interventional Cardiology. Percutaneous Closure of Postinfarction Ventricular Septal Defect

Patrick A. Calvert, PhD, MRCP; James Cockburn, MD, MRCP; Dylan Wynne, PhD, FRACP; Peter Ludman, MD, FRCP; Bushra S. Rana, MD, MRCP; David Northridge, MD; Michael J. Mullen, MD, FRCP; Iqbal Malik, PhD, FRCP; Mark Turner, MD; Saib Khogali, MD, FRCP; Gruschen R. Veldtman, MD, FRCP, MD; Martin Been, MD; Rob Butler, MD; John Thomson, MD, FRCP; Jonathan Byrne, PhD, FRCP; Philip MacCarthy, PhD, FRCP; Lindsay Morrison, MD, FRCP; Len M. Shapiro, MD, FRCP; Ben Bridgewater, MD; Jo de Giovanni, MD; David Hildick-Smith, MD, FRCP

Background: Postinfarction ventricular septal defect carries a grim prognosis. Surgical repair offers reasonable outcomes in patients who survive a healing phase. Percutaneous device implantation represents a potentially attractive early alternative.

09 abril 2014

CIRCULATION. Interventional Cardiology. High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization

Gilles Montalescot, MD, PhD; Grégoire Rangé, MD; Johanne Silvain, MD, PhD; Jean-Louis Bonnet, MD; Ziad Boueri, MD; Olivier Barthélémy, MD; Guillaume Cayla, MD, PhD; Loic Belle, MD; Eric Van Belle, MD, PhD; Thomas Cuisset, MD, PhD; Simon Elhadad, MD; Christophe Pouillot, MD; Patrick Henry, MD, PhD; Pascal Motreff, MD, PhD; Didier Carrié, MD, PhD; Hélène Rousseau, PhD; Pierre Aubry, MD; Jacques Monségu, MD; Pierre Sabouret, MD; Stephen A. O’Connor, MB BCh, MD; Jérémie Abtan, MD; Mathieu Kerneis, MD; Christophe Saint-Etienne, MD; Farzin Beygui, MD, PhD; Eric Vicaut, MD, PhD; Jean-Philippe Collet, MD, PhD; for the ARCTIC Investigators

Background: Individualizing antiplatelet therapy after platelet function testing did not improve outcome after coronary stenting in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting (ARCTIC) study. Whether results are different during the phase of secondary prevention starting after hospital discharge, when periprocedural events have been excluded, is unknown.

01 abril 2014

CIRCULATION. Cardiovascular Surgery. Stroke After Aortic Valve Surgery

Steven R. Messé, MD; Michael A. Acker, MD; Scott E. Kasner, MD; Molly Fanning, BS; Tania Giovannetti, PhD; Sarah J. Ratcliffe, PhD; Michel Bilello, MD, PhD; Wilson Y. Szeto, MD; Joseph E. Bavaria, MD; W. Clark Hargrove III,, MD; Emile R. Mohler III,, MD; Thomas F. Floyd, MD; for the Determining Neurologic Outcomes from Valve Operations (DeNOVO) Investigators

Background: The incidence and impact of clinical stroke and silent radiographic cerebral infarction complicating open surgical aortic valve replacement (AVR) are poorly characterized.

17 marzo 2014

CIRCULATION. Epidemiology and Prevention. Time-Dependent Changes in Atherosclerotic Plaque Composition in Patients Undergoing Carotid Surgery

Guus W. van Lammeren, MD, PhD*; Hester M. den Ruijter, PhD*; Joyce E. P. Vrijenhoek, MD; Sander W. van der Laan, MSc; Evelyn Velema, MSc; Jean-Paul P. M. de Vries, MD, PhD; Dominique P. V. de Kleijn, PhD; Aryan Vink, MD, PhD; Gert Jan de Borst, MD, PhD; Frans L. Moll, MD, PhD; Michiel L. Bots, MD, PhD; Gerard Pasterkamp, MD, PhD

Background: Time-dependent trends in the incidence of cardiovascular disease have been reported in high-income countries. Because atherosclerosis underlies the majority of cardiovascular diseases, we investigated temporal changes in the composition of atherosclerotic plaques removed from patients undergoing carotid endarterectomy.

23 mayo 2014

CIRCULATION. Valvular Heart Disease. Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement

Suzanne V. Arnold, MD, MHA; Matthew R. Reynolds, MD, MSc; Yang Lei, MS; Elizabeth A. Magnuson, ScD; Ajay J. Kirtane, MD, SM; Susheel K. Kodali, MD; Alan Zajarias, MD; Vinod H. Thourani, MD; Philip Green, MD; Josep Rodés-Cabau, MD; Nirat Beohar, MD; Michael J. Mack, MD; Martin B. Leon, MD; David J. Cohen, MD, MSc; on behalf of the PARTNER Investigators

Background: Transcatheter aortic valve replacement (TAVR) is a less invasive option for treatment of high-risk patients with severe aortic stenosis. We sought to identify patients at high risk for poor outcome after TAVR using a novel definition of outcome that integrates quality of life with mortality.

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Jeong Hoon Yang, MD∗; Joo-Yong Hahn, MD∗; Young Bin Song, MD∗; Seung-Hyuk Choi, MD∗; Jin-Ho Choi, MD∗; Sang Hoon Lee, MD∗; Joo Han Kim, MD‡; Young-Keun Ahn, MD‡; Myung-Ho Jeong, MD‡; Dong-Joo Choi, MD§; Jong Seon Park, MD‖; Young Jo Kim, MD‖; Hun Sik Park, MD¶; Kyoo-Rok Han, MD#; Seung Woon Rha, MD∗∗; Hyeon-Cheol Gwon, MD∗

Objectives: This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI).

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Prognostic Value of “Routine” Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention. The Prospective Long-Term Observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING Study

Michael J. Zellweger, MD∗; Gregor Fahrni, MD∗; Myriam Ritter, MD∗; Raban V. Jeger, MD∗; Damian Wild, MD†; Peter Buser, MD∗; Christoph Kaiser, MD∗; Stefan Osswald, MD∗; Matthias E. Pfisterer, MD∗

Objective: This study sought to evaluate the prognostic value of routine stress myocardial perfusion scintigraphy (MPS) 5 years after percutaneous coronary intervention (PCI).

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. A Cohort Study in ST-Segment Elevation Myocardial Infarction and Comprehensive Meta-analysis

Wouter J. Kikkert, MD∗; Ronak Delewi, MD∗; Dagmar M. Ouweneel, MSc∗; Sophie H. van Nes∗; Marije M. Vis, MD, PhD∗; Jan Baan, MD, PhD∗; Karel T. Koch, MD, PhD∗; George D. Dangas, MD, PhD†; Roxana Mehran, MD†; Robbert J. de Winter, MD, PhD∗; Ron J.G. Peters, MD, PhD∗; Jan J. Piek, MD, PhD∗; Jan G.P. Tijssen, PhD∗; Jose P.S. Henriques, MD, PhD∗

Objectives: This study sought to investigate the prognostic value of access site bleeding (ASB) and non-ASB for recurrent ischemic outcomes and mortality in patients with ST-segment elevation myocardial infarction (STEMI).

13 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions. A Randomized Long Drug-Eluting Stent V Trial

Jong-Young Lee, MD, PhD, Duk-Woo Park, MD, PhD, Young-Hak Kim, MD, PhD, Jung-Min Ahn, MD, Won-Jang Kim, MD, PhD, Soo-Jin Kang, MD, PhD, Seung-Whan Lee, MD, PhD, Cheol Whan Lee, MD, PhD, Seong-Wook Park, MD, PhD, Sung-Cheol Yun, PhD, Tae-Hyun Yang, MD, PhD, Bong-Ki Lee, MD, PhD, Nae-Hee Lee, MD, PhD, Joo-Young Yang, MD, PhD, Won-Yong Shin, MD, PhD, Hun Sik Park, MD, PhD, Kee-Sik Kim, MD, PhD, Seung Ho Hur, MD, PhD, Sung Yun Lee, MD, PhD, Jong-Seon Park, MD, PhD, Yun Seok Choi, MD, PhD, Seung Uk Lee, MD, PhD, Sung-Ho Her, MD, PhD and Seung-Jung Park, MD, PhD

Background: Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo percutaneous coronary intervention. The current study, therefore, evaluated 2 innovative drug-eluting stents for the management of long-lesion coronary artery disease.

06 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. Two-Year Final Clinical Results

Yoshitaka Shiratori, MD, Clarissa Cola, MD, Salvatore Brugaletta, MD, PhD, Luis Alvarez-Contreras, MD, Victoria Martín-Yuste, MD, PhD, Bruno García del Blanco, MD, Rafael Ruiz-Salmeron, MD, Jose Díaz, MD, Eduardo Pinar, MD, Vicens Martí, MD, PhD, Juan García-Picart, MD and Manel Sabaté, MD, PhD

Background: Most drug-eluting stents currently in use are coated with a polymer carrying the drug that is released for several weeks. However, a durable polymer may provoke hypersensitive reaction, delayed artery healing, and eventually stent thrombosis. The aim of this study was to investigate the safety and efficacy of a polymer-free paclitaxel-eluting stent (PF-PES) versus a polymer-based PES (PB-PES).

27 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction. Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction

Diego Fernández-Rodríguez, MD, Ander Regueiro, MD, Salvatore Brugaletta, MD, PhD, Victoria Martín-Yuste, MD, PhD, Mónica Masotti, MD, PhD, Angel Cequier, MD, PhD, Andrés Iñíguez, MD, PhD, Antonio Serra, MD, PhD, Rosana Hernández-Antolín, MD, PhD, Vicente Mainar, MD, PhD, Marco Valgimigli, MD, PhD, Maurizio Tespili, MD, PhD, Pieter den Heijer, MD, PhD, Armando Bethencourt, MD, PhD, Nicolás Vázquez, MD, PhD, Patrick W. Serruys, MD, PhD and Manel Sabaté, MD, PhD on behalf of the EXAMINATION investigators

Background: Manual thrombus aspiration (TA) is effective to reduce the thrombus burden during primary percutaneous coronary intervention for ST-elevation myocardial infarction. The objective of this study is to assess the impact of manual TA on stent implantation during primary percutaneous coronary intervention.

03 junio 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Acute Changes of Mitral Valve Geometry During Interventional Edge-to-Edge Repair With the MitraClip System Are Associated With Midterm Outcomes in Patients With Functional Valve Disease

Robert Schueler, MD, Diana Momcilovic, MD, Marcel Weber, MD, Armin Welz, MD, Nikos Werner, MD, Cornelius Mueller, MD, Alexander Ghanem, MD, Georg Nickenig, MD and Christoph Hammerstingl, MD

Background: Transcatheter mitral valve repair (TMVR) is a treatment option in patients with symptomatic functional or degenerative mitral regurgitation (DMR) at high surgical risk. The acute effect of MitraClip procedure on mitral valve (MV) annular geometry and its relation to functional outcomes is unclear. We sought to assess immediate effect of TMVR on MV annular geometry with 3-dimensional (3D) transesophageal echocardiography and the association of MV diameter reduction with functional response after 6 months.

30 abril 2014

CIRCULATION. Coronary Heart Disease. Effects of Sex on Coronary Microvascular Dysfunction and Cardiac Outcomes

Venkatesh L. Murthy, MD, PhD; Masanao Naya, MD, PhD; Viviany R. Taqueti, MD; Courtney R. Foster, MS; Mariya Gaber, MLA; Jon Hainer, BS; Sharmila Dorbala, MD, MPH; Ron Blankstein, MD; Ornella Rimoldi, MD; Paolo G. Camici, MD; Marcelo F. Di Carli, MD

Background: Coronary microvascular dysfunction (CMD) is a prevalent and prognostically important finding in patients with symptoms suggestive of coronary artery disease. The relative extent to which CMD affects both sexes is largely unknown.